BR0316737A - Métodos e composições para induzir apoptose em células cancerosas - Google Patents

Métodos e composições para induzir apoptose em células cancerosas

Info

Publication number
BR0316737A
BR0316737A BR0316737-2A BR0316737A BR0316737A BR 0316737 A BR0316737 A BR 0316737A BR 0316737 A BR0316737 A BR 0316737A BR 0316737 A BR0316737 A BR 0316737A
Authority
BR
Brazil
Prior art keywords
cancer cells
compositions
methods
inducing apoptosis
apoptosis
Prior art date
Application number
BR0316737-2A
Other languages
English (en)
Inventor
Marc Nasoff
Quinn L Deveraux
Deborah A Knee
Pedro Aza-Blanc
Garret M Hampton
Klaus Wagner
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BR0316737A publication Critical patent/BR0316737A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA INDUZIR APOPTOSE EM CéLULAS CANCEROSAS". Agonistas de anticorpo de Anti-DR4 ou Anti-DR5, combinados com agentes de indução de apoptose, sinergisticamente induzem apoptose em células cancerosas.
BR0316737-2A 2002-11-27 2003-11-25 Métodos e composições para induzir apoptose em células cancerosas BR0316737A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42984202P 2002-11-27 2002-11-27
US44896003P 2003-02-21 2003-02-21
US49471403P 2003-08-12 2003-08-12
US50490103P 2003-09-22 2003-09-22
PCT/US2003/037940 WO2004050895A2 (en) 2002-11-27 2003-11-25 Methods and compositions for inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
BR0316737A true BR0316737A (pt) 2005-12-13

Family

ID=32475709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316737-2A BR0316737A (pt) 2002-11-27 2003-11-25 Métodos e composições para induzir apoptose em células cancerosas

Country Status (17)

Country Link
US (2) US7229617B2 (pt)
EP (1) EP1576179B1 (pt)
JP (1) JP2006514096A (pt)
KR (3) KR20070122578A (pt)
AT (1) ATE481092T1 (pt)
AU (1) AU2003297579A1 (pt)
BR (1) BR0316737A (pt)
CA (1) CA2507077A1 (pt)
CO (1) CO5640147A2 (pt)
DE (1) DE60334247D1 (pt)
EC (1) ECSP055818A (pt)
MX (1) MXPA05005726A (pt)
NO (1) NO20052922L (pt)
PL (1) PL210174B1 (pt)
PT (1) PT1576179E (pt)
RU (1) RU2379056C2 (pt)
WO (1) WO2004050895A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
CN1610696A (zh) * 2001-12-20 2005-04-27 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7229617B2 (en) * 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
US20060115453A1 (en) * 2004-11-12 2006-06-01 Yaffe Michael B Methods and compositions for treating cellular proliferative diseases
WO2006104672A1 (en) * 2005-03-24 2006-10-05 Irm Llc Enhancing myc-dependent sensitivity of cancer to dr5 agonists
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
CA2564872C (en) * 2005-10-25 2010-12-21 Aegera Therapeutics Inc. Iap bir domain binding compounds
EP1957540B1 (en) * 2005-12-02 2012-06-13 Genentech, Inc. Binding polypeptides and uses thereof
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
RU2010101416A (ru) * 2007-06-19 2011-07-27 Такеда Фармасьютикал Компани Лимитед (Jp) Профилактическое/лекарственное средство от рака
US20100272706A1 (en) 2007-06-22 2010-10-28 Jason Mercer Antivirals
EP2399610A3 (en) 2007-09-24 2012-09-05 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009155709A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
AU2009293545A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
CA2745775A1 (en) * 2008-12-18 2010-07-15 Centre National De La Recherche Scientifique - Cnrs- Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof
US9527915B2 (en) 2009-11-05 2016-12-27 The Uab Research Foundation Treating basal-like genotype cancers
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
US10016440B2 (en) * 2010-04-21 2018-07-10 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
ES2675847T3 (es) 2010-10-29 2018-07-13 Daiichi Sankyo Company, Limited Nuevo anticuerpo anti-DR5
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2651917A1 (en) 2010-12-13 2013-10-23 Novartis AG Dimeric iap inhibitors
WO2012151390A2 (en) * 2011-05-03 2012-11-08 Albert Einstein College Of Medicine Of Yeshiva University A therapeutic and diagnostic target gene in acute myeloid leukemia
RU2488408C1 (ru) * 2012-03-22 2013-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Средство и способ индукции апоптоза опухолевых клеток
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP3250601A4 (en) 2015-01-26 2018-07-11 MacroGenics, Inc. Multivalent molecules comprising dr5-binding domains
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
WO2019173499A1 (en) 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 17-beta-hydroxywithanolides and use thereof in treating cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ES2109945T3 (es) 1990-06-01 1998-02-01 Chiron Corp Composiciones y procedimientos para identificar moleculas biologicamente activas.
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AUPQ599500A0 (en) 2000-03-02 2000-03-23 Walter And Eliza Hall Institute Of Medical Research, The Novel peptides, modulatory agents therefor and methods of using them
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
CA2420534A1 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
HU230378B1 (hu) * 2001-11-01 2016-03-29 Uab Research Foundation Anti-DR5 ellenanyagok és anti-DR4 ellenanyagok és más terápiás ágensek kombinációi
US7229617B2 (en) 2002-11-27 2007-06-12 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
MXPA06014795A (es) 2004-06-21 2007-03-26 Univ Washington Anticuerpos contra el virus del nilo occidental y usos terapeuticos y profilacticos de los mismos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .

Also Published As

Publication number Publication date
RU2005120167A (ru) 2006-03-10
CO5640147A2 (es) 2006-05-31
ECSP055818A (es) 2006-01-27
EP1576179A2 (en) 2005-09-21
KR20090046973A (ko) 2009-05-11
CA2507077A1 (en) 2004-06-17
EP1576179A4 (en) 2007-06-06
NO20052922D0 (no) 2005-06-15
PL377726A1 (pl) 2006-02-06
MXPA05005726A (es) 2005-08-16
US8173128B2 (en) 2012-05-08
RU2379056C2 (ru) 2010-01-20
PL210174B1 (pl) 2011-12-30
NO20052922L (no) 2005-08-17
DE60334247D1 (de) 2010-10-28
US7229617B2 (en) 2007-06-12
JP2006514096A (ja) 2006-04-27
US20070128204A1 (en) 2007-06-07
EP1576179B1 (en) 2010-09-15
ATE481092T1 (de) 2010-10-15
KR20070122578A (ko) 2007-12-31
US20050079172A1 (en) 2005-04-14
AU2003297579A1 (en) 2004-06-23
KR100915257B1 (ko) 2009-09-03
WO2004050895A2 (en) 2004-06-17
WO2004050895A3 (en) 2005-12-08
KR20050094811A (ko) 2005-09-28
PT1576179E (pt) 2010-12-21

Similar Documents

Publication Publication Date Title
BR0316737A (pt) Métodos e composições para induzir apoptose em células cancerosas
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
TW200501960A (en) Synergistic kits and compositions for treating cancer
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
MX2009006505A (es) Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para usarlas en el tratamiento de la presbiopia.
MY160041A (en) Compositions and methods for treating parasitic infections
AR046184A1 (es) Composicion nutricional en contra de los efectos colaterales de quimioterapia y radioterapia
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
EA200801430A1 (ru) Производные триазола
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
NO20053339L (no) Levalbuterolsalt.
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
UY28345A1 (es) Compuestos novedosos
BRPI0519216A2 (pt) reduÇço no crescimento de cabelos ou pÊlos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]